Clinical Trials Browser

Phase 1 × vorasidenib × 30 days × Clear all

NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Phase 1 Active not recruiting

Astrocytoma, Oligodendroglioma